No retraction, correction or concern found when last checked on Oct 21, 2026.
Hydrogel Encapsulation of Mesenchymal Stem Cells and Their Derived Exosomes for Tissue Engineering
Parisa Khayambashi, Janaki Iyer, Sangeeth Pillai and 3 more
International Journal of Molecular Sciences · 2021 · Review · CC BY
Abstract
Tissue engineering has been an inveterate area in the field of regenerative medicine for several decades. However, there remains limitations to engineer and regenerate tissues. Targeted therapies using cell-encapsulated hydrogels, such as mesenchymal stem cells (MSCs), are capable of reducing inflammation and increasing the regenerative potential in several tissues. In addition, the use of MSC-derived nano-scale secretions (i.e., exosomes) has been promising. Exosomes originate from the multivesicular division of cells and have high therapeutic potential, yet neither self-replicate nor cause auto-immune reactions to the host. To maintain their biological activity and allow a controlled release, these paracrine factors can be encapsulated in biomaterials. Among the different types of biomaterials in which exosome infusion is exploited, hydrogels have proven to be the most user-friendly, economical, and accessible material. In this paper, we highlight the importance of MSCs and MSC-derived exosomes in tissue engineering and the different biomaterial strategies used in fabricating exosome-based biomaterials, to facilitate hard and soft tissue engineering.
Full text
From PubMed Central, U.S. National Library of Medicine, as current on Oct 21, 2026. Paragraph numbers are ours, so an answer can point at one.
1. Tissue Regeneration and MSCs
Bone regeneration for critical size defects is challenging, and even the most commonly used approaches in bone reconstruction, such as autologous and allogenic bone grafts, do not meet all the requirements of a bioactive material. For autologous grafts, the quantity of the harvested bone tissue is limited, and the procedure is sometimes associated with increased donor site morbidity. Failures due to mechanical instability and immunological rejection after the surgery paved the way for the development of alternative techniques for bone regeneration and defect repair. Tissue engineering deals with the combined application of principles of life sciences and engineering towards understanding the structural and functional relationship in physiological and pathological tissues, involving bioactive materials. A biomaterial can be described as any natural or synthetic substance or combination of substances that, when applied intimately into a functional system, autonomously replaces and restores the tissues of the body.
This multidisciplinary science uses the properties of a porous biocompatible and biodegradable material in the form of two dimensional or three-dimensional scaffold or template upon which the cells are seeded to promote growth in the tissue microenvironment. Biomaterials either act as an in vitro template to aid in tissue engineering, with adequate cell–cell interaction and growth factors, or as an aid in transplanting the regenerated tissue in vivo to integrate structurally and functionally with the system. Biomaterials commonly encountered in tissue engineering comprise of natural and synthetic polymers, and ceramics. Three-dimensional hydrophilic polymers, such as hydrogels, have emerged as a bioactive scaffold material in the recent past, which are commonly used in drug delivery and cell encapsulation.
Cell-encapsulated hydrogels demonstrate prolonged fundamental and operational consistency and are widely applied in regenerative therapy. The developments in cell-encapsulated hydrogel therapies have been improved by the heightened ease of using mesenchymal stem cells (MSCs) with them. When a combination of stem cells and hydrogels are used, certain considerations are necessary. For instance, when MSCs are used in three-dimensional (3D) microenvironments, their differentiation efficiency into osteocytes, hepatocytes, or adipocytes is increased as compared to two-dimensional (2D) cultures. MSCs also have shown enhanced differentiation capacity when cultured in proximity to other cells, such as hematopoietic stem cells (HSCs) and human umbilical vein endothelial cells (HUVECs). The cell encapsulation method is also reportedly dependent on the shape and size of the vehicle that delivers the MSCs. The 3D environment, whether it is a hydrogel or bioprinted microfluid droplets, is required to be tailored to the target tissue for optimal tissue regeneration.
In this regard, the MSCs’ secretions have gained special attention as a regenerative tool compared to other cell-based therapies. Initially identified in the 1960s, MSCs were first described as spindle-shaped cells originating from bone marrow that could regulate the quiescence and self-renewal of hematopoietic stem cells through the release of paracrine factors. These cells are rare, heterogenous, and, in addition to bone marrow, have been successfully isolated from placenta, amniotic fluid (AF), umbilical cord blood (CB), Wharton’s jelly (WJ), and adipose tissue (AD). MSCs are easy to isolate from adult tissues, have a large capacity for ex vivo expansion, and have proven to be efficiently therapeutic in many diseases.
The International Society for Cellular Therapy has released the three minimal requirements to define multipotent MSCs: first, MSCs being plastic-adherent; second, expressing CD105, CD73, and CD90 while not expressing CD45, CD34, CD14 or CD11b, CD79α or CD19, and HLA-DR surface molecules; and third, having differentiation capacity into osteoblasts, adipocytes, and chondroblasts in vitro.
Treating sites of injury using MSCs has its own disadvantages. An estimated more than 99% of these cells get trapped in the spleen, lungs, and liver, and those that do approach the targeted tissue have a low survival time and are predisposed to cause thrombosis, fever, and tumors. An alternative approach would be to consider the paracrine mechanisms of MSCs, especially the nanometer vesicles, exosomes, as the source of biomaterials for tissue repair (Figures 3A and 4). Recent studies have identified MSC exosomes as the mediator in carrying the restorative agents. In addition to lowering the potential risks of cell-based therapy, processing, and storage conditions, exosomes are less sensitive than MSCs. Exosomes will not self-replicate and consequently would not cause tumor formation.
2. MSCs and Exosomes
Although the benefits of exosomes are well-known, the drawbacks of delivering a therapeutic dosage of exosomes, especially through systemic injections, may outweigh their advantages. As for the biological effects of exosomes to be prompted, they are required to be internalized via endocytosis by the targeted cell, otherwise they rapidly would be cleared from the blood circulation and may even accumulate in the liver, spleen, lungs, and gastrointestinal tract. Direct intravenous, intraperitoneal, or subcutaneous injections of exosomes can mount a reaction by macrophages in the reticuloendothelial system, leading to their rejection. Bodily and topical applications on skin or ocular surfaces has shown short half-lives after interacting with sweat, tears, and the epithelial barrier (tight junctions). On the other hand, the difficulties in exosome purification and mass-scale production emanate from the expensive manufacturing protocols that require consistency and purity of nanometer-sized biomaterials. Therefore, delivering exosomes entails a more efficient method to elude from being cleared by the host body.
2.1. Characterization of Exosomes
As demonstrated in Figure 1 and Figure 3B, a plethora of methods are being tested to isolate and characterize exosomes from different types of cells (Figure 3A). Due to the size distribution (50–120 nm) and the delicate membranous nature of the exosomes, characterizing them before their involvement in biomaterials is critical to optimize the desired effect in the target tissue. These characterizations consist of assays to evaluate the interactions of the exosomes with the surrounding tissue, surface markers, their proteomics profile, their morphology, and size. From 1 mL of culture medium, typically less than 1 µg of exosome proteins could be isolated whereas the suggested therapeutic dosage for humans would require 100–1000 times this value. Thus, the need for a biocompatible, bioactive, and biodegradable material for delivering therapeutics with exosomes has brought the attention of biomedical science to porous hydrogels.
2.2. Exosomes and Biomaterials
Due to the reasons indicated earlier, the most pertinent application of exosomes in regenerative medicine is by conjoining them with a biomaterial. Several studies have evaluated this combination; for instance, Shi et al. reported accelerated angiogenesis, neurogenesis, reepithelization, and collagen formation on investigating a chitosan/silk hydrogel sponge as a carrier for gingival MSC-derived exosomes. In another study, human placenta-derived MSC exosomes, when encapsulated in a chitosan hydrogel, have also shown enhanced angiogenesis and tissue regeneration in a mouse hindlimb.
As illustrated in Figure 2, in tissue regeneration, and more specifically during bone formation, osteoblastic cells begin to proliferate and produce an osteogenic matrix, leading to the formation of a new bone structure and an increased metabolic demand, which is reciprocated by an increase in the blood flow rate (BFR) and vascular density (VD). At this point, endogenous stem cells or its secreted exosomes have to be recruited to enhance neovascularization. This recruitment is sensitive and essential, and its efficiency determines the success rate of procedures such as allograft tissues in bone reconstruction surgeries.
Perfecting the efficiency of a biomaterial to facilitate osteogenesis and angiogenesis is the driving force behind several studies incorporating biomaterials and tissue engineering. Therefore, finding the right cell type to isolate exosomes from (Figure 3A,B) and the corresponding method to characterize these exosomes are as important as discovering the suitable method to load them with therapeutics and embed them in the proper hydrogel (Figure 4). As depicted in Figure 3, exosome donor cells vary from the different types of cells, such as immature dendritic cells; model cell lines, such as HeLa and HEK-293 and murine melanoma cells; human platelet lysate (PL); and MSCs, see also.
As shown in Figure 4, methods to load the exosomes with therapeutics include passive or active methods. Passive methods include incubation with exosomes and incubation with donor cells. Active methods include sonication, freeze–thaw cycles, electroporation, extrusion, incubation, click chemistry, and antibodies. Methods such as chemical-based transfection, transfection of exosome-producing cells, and cell activation are among the other techniques for loading exosomes with therapeutics.
3. Exosomes and Hydrogels
Hydrogels are three-dimensional polymers that are physically or chemically cross-linked in structure, function as biocompatible scaffolds, and demonstrate a strong affinity for water. Hydrogels possess unique properties that can be exploited towards versatile biomedical applications, such as in:A hydrophilic porous structure—an ability to absorb and retain water while maintaining structural integrity, allowing the free diffusion of particulate materials.Shear and compressive stress—Young’s modulus and atomic force microscopy of hydrogels determine the cellular migration and proliferation in biomaterial scaffolds.Volume phase transition or gel-sol transition—depending on the nature and magnitude of the external stimuli, such as physical (electromagnetic fields, temperature, and pressure) and chemical (pH and ions), the hydrogels exhibit reversible volume changes.Degree of flexibility—the structural lattice of the hydrogels formed by the crosslinked monomer–polymer networking, with covalent and non-covalent bonds, enhance their adaptability to the microenvironment, mimicking the tissue.Degradability—the synchronized degradation of the hydrogels to support cellular growth in the tissue microenvironment.
A hydrophilic porous structure—an ability to absorb and retain water while maintaining structural integrity, allowing the free diffusion of particulate materials.
Shear and compressive stress—Young’s modulus and atomic force microscopy of hydrogels determine the cellular migration and proliferation in biomaterial scaffolds.
Volume phase transition or gel-sol transition—depending on the nature and magnitude of the external stimuli, such as physical (electromagnetic fields, temperature, and pressure) and chemical (pH and ions), the hydrogels exhibit reversible volume changes.
Degree of flexibility—the structural lattice of the hydrogels formed by the crosslinked monomer–polymer networking, with covalent and non-covalent bonds, enhance their adaptability to the microenvironment, mimicking the tissue.
Degradability—the synchronized degradation of the hydrogels to support cellular growth in the tissue microenvironment.
Owing to this versatility, hydrogels mimic natural tissue, and hence have been widely applied and constantly modified to enhance different biomedical applications. Augmentation of the hydrogel scaffolds, to improve cellular migration, proliferation, and differentiation, promotes their application in tissue engineering, regenerative medicine, adhesive medicine, cell-encapsulation matrices, and drug-delivery systems.
Hydrogels have been widely used as a carrier for the sustained local drug delivery of treated exosomes, such as a chitosan/silk hydrogel sponge as a substrate for human gingival MSC-derived exosomes and human placental-derived MSCs. The hydrophilic and cross-linking behavior of hydrogels facilitate their ability for controlled drug release, and have proven impactful in the fields of angiogenesis, osteogenesis, oncology, immunology, and pain management.
3.1. Hydrogel-Exosome Encapsulation Strategies
Development of smart biomaterials has unfastened the scope for drug encapsulation. This has led to efficient and sustained delivery of biomolecules in a site-specific manner, such as hydrogels. Using hydrogels has facilitated the process of harnessing the therapeutic benefits of exosomes in bone tissue engineering. There are three common strategies for encapsulating exosomes into a hydrogel matrix.
1. Combining exosomes with polymers followed by addition of crosslinkers to induce gelation (Figure 5A). This technique was explained by Qin et al., where they used thiolated hyaluronic acid (HA), gelatin, and heparin as the main components. Bone marrow stem cell-derived exosomes were incorporated into this polymer and polyethylene glycol diacrylate (PEGDA) was used as a gelation agent. This is based on covalent crosslinking of the active precursors. They are an attractive choice of exosome and cell encapsulation since they provide high tunability of the hydrogels, allowing control over the mechanical properties and degradation rate. However, one common concern arises with the addition of new compounds, such as the crosslinkers, which can be potentially be cytotoxic to the biomolecules. One additional advantage with this technique is the use of the macromolecular monomers usually derived from the biocompatible polymers.
2. Physical incorporation of hydrogels or “breathing” technique (Figure 5B). This method involves two basic steps. First, the already swollen hydrogel is placed into a solvent that removes the water present in the hydrogel. The hydrogel is then soaked in an aqueous solution containing the exosomes, causing the breathing-in of the exosomes into the porous hydrogel. This technique is based on the simple principle of smart hydrogels forming swollen structures when kept in water, but on exposure to solvents with lower polarity becomes collapsed and undergo a phase transition. However, to use this technique, the pore size of the hydrogel should be moldable and larger than the exosomes or the stem cells that need to be encapsulated. Once inside, the loosely attached exosomes will leach out when exposed to the site of action.
3. Mixing of the exosomes with both the polymers in solution and crosslinkers simultaneously (Figure 5C). This leads to an in situ gelation, allowing targeted delivery of the exosomes, as described in the study by Wang et al., where they used adipose-derived exosomes with polypeptides for wound healing and skin regeneration. This is usually achieved by a dual chamber syringe that can inject the hydrogel components with exosomes directly to the site.. In situ gelation can be achieved by several mechanisms, such as UV irradiation, ion-exchange, pH change, and temperature changes. This technique is highly notable in filling critical size defects with complex geometries, allowing good viability of the incorporated biomolecules. These injectable scaffolds will have the desired native tissue properties, and thus can function without external inducers.
3.2. Hydrogel Combinations for Exosome and Stem Cell Encapsulation
Sustained delivery of exosomes has been a widely studied research area in tissue engineering. Although in its infancy, the potential of hydrogel-based delivery systems is tremendous. Table 1 summarizes some of the most significant hydrogel-based biomaterial strategies used to incorporate exosomes and their parent stem cells in hydrogels for various applications in biomedicine.
To date, HA, gelatin, chitosan, and polypeptide-based hydrogels have been used for encapsulating exosomes from different cell sources. Although the mechanism of embedding exosomes within hydrogels includes one of the three strategies described in Figure 5, minor modifications made to the principal technique improves the fabrication ease and allows efficient delivery of the exosomes. For example, Liu et al. used a photoinduced imine crosslinker by reacting the aldehyde groups, generated by the light irradiation of the O-nitro benzyl alcohol groups, to modified HA and amino acids on gelatin. PGLA has been largely used as a material of choice for exosome encapsulation and a widely used biocompatible scaffold for tissue regeneration.
The mussel-inspired technique was used by Lee et al. for immobilization using pDA (polydopamine) to provide a more efficient coating on the PLGA substrate. They immobilized the bone-forming peptides-1 (BFP-1) using this technique, which allowed a slow release of BFP-1 and showed that combining hASCs and PLGA/pDA can enhance bone formation. Most recently, Wang et al. described a highly efficient injectable self-healing hydrogel fabrication using a Schiff base linkage for applications in severe wound healing. They constructed a methyl-cellulose (MC)–chitosan (CS) combination of a hydrogel with placental cell-derived exosomes. The MC- and CS-grafted polyethylene glycol were synthesized using DCC (dicyclohexyl- carbodiimide) and EDC (1-(3-dimethylaminopropyl)-3-ethylcarbodiimide) reactions. Both these polymer solutions were mixed together along with exosomes to fabricate the complex hydrogel.
Scaffold production, using physical freeze drying and crosslinking methods, have provided good results in terms of cell encapsulation. However, Chen et al. described fabrication of a 3D-printed decellularized extracellular matrix (ECM) with gelatin methacrylate loaded with exosomes from MSCs using desktop-stereolithography technology. This technique allowed the synthesis of radically oriented channels, which provides superior cartilage regeneration by directing the migration of the chondrocytes and thus repairing osteochondral defects.
Currently, all materials commonly used for exosome encapsulation are naturally derived owing to their ease of handling and fabrication, higher biocompatibility, and ability to simulate ECM-like conditions. Although there might be harmful effects due to the presence of crosslinkers and residual peptides during hydrogel formation, they are highly formable and can be constructed for patient-specific needs, making them the key biomaterial for drug delivery and other tissue-regeneration applications. Still, the challenges in their use include a lack of slow-releasing potential, inability to induce surface modifications, and timing the delivery of exosomes or bioactive molecules to coincide with the natural healing and regenerative processes.
3.3. Hydrogels and Exosomes in Hard Tissue Regeneration
Inducing hard tissue regeneration with a controlled release of drugs requires the presence of suitable cells as the foundation. Bone regeneration is based on three key factors: stem cells, scaffolds, and growth factors. Figure 2 depicts the cascade of events for healing of a fracture and consists of a complex physical process for delivering drugs and biomaterials. Amongst the hard tissues, regeneration of cartilage remains challenging due to its avascular nature. Given the high incidence of age-related diseases, such as osteoarthritis and injuries, it becomes imperative to look for alternative regenerative procedures.
Scaffolds and grafts have been used for ages for bone regeneration. Especially for hard tissue repair, artificial grafts and scaffolds offer the advantage of having less morbidity as there is no need for secondary surgery or donors. They are also cheaper and customizable to the required needs. There have been numerous advances to inculcate their inductive nature by fabrication of hybrid biomaterials with multipotential cells and their released factors. As depicted in Table 2, each biomaterial releases its secretory content at a different rate, and hence has a different potential clinical use.
Exosome-integrated scaffolds helped in restoring the mitochondrial function of degrading cartilage in an osteoarthritic cell model. Chen et al. identified the proteins associated with degrading mitochondrial function through protein enrichment analysis, which were less expressed in treated cells, leading to the rescue from osteoarthritic degradation. Additionally, through transwell migration assays, it was found that the MA matrix with exosomes and ECM proteins had the maximum influence on chondrocyte migration.
Table 2 lists the studies that had tested additional parent cell types and combinations of assisted matrices with hydrogel compositions. One of the most commonly used compositions is PLGA, which is applied as a biocompatible scaffold for tissue regeneration. The challenge with PLGA is its lack of ability for slow-releasing surface modification. Such a feature becomes essential while timing the delivery of the exosomes or bioactive molecules to coincide with the natural healing and regenerative process. To overcome this issue, the release profile of the PLGA polymeric scaffolds was assessed by combining it with polydopamine (pDA), a mussel-inspired biomaterial that allows higher adhesions. The exosome burst release from PLGA/pDA was recorded to be significantly slower (8 days) than the PLGA samples (4 days). In another study, Yang et al. found better release kinetics with 71.2% of exosomes being released over 14 days using hydroxyapatite (HAP) and hyaluronic acid–alginate gel (HA–ALG) hydrogels.
Each study entails a specific physiological pathway exploited for osteogenic induction. For instance, Li et al. used hASC-derived exosomes two days after osteogenic induction to potentiate the osteogenesis-promoting factor production. In the same study, the chemotactic and proliferative effect on BMSCs were tested and it was found that during the phenotypic translation of the MSCs, its chemotactic and proliferative effects may be lost. Another important pathway found to be involved with exosome release from stem cells is the PI3Akt pathway, as the exosomes derived from human-induced pluripotent stem cells (hIPSCs), integrated into tricalcium phosphate, were seen to enhance bone regeneration through the phosphoinositide 3-kinase (PI3Akt) pathway.
3.4. Hydrogels and Exosomes in Soft Tissue Regeneration
Soft tissue regeneration is required in cases of delayed wound healing as in diabetic patients or large soft tissue wounds like burns. Biomaterials for soft tissue wound healing are required to be able to adapt to the uneven morphology and mobility of the defect and also to have adhesiveness to the surrounding tissue to offer complete coverage as well as prevent exposure of the healing site to the environment (Table 3). The characteristics of assisted matrices for soft tissue regeneration include having a thermally responsive gelation, water retaining ability, as well as antibacterial and adhesive properties. Hydrogels, such as FHE, offer these properties and, when loaded with exosomes, have shown enhanced angiogenic potential. Regenerative medicine has offered countless approaches for assisted wound healing. With the recently identified advantages of exosomes, efforts are being made to integrate past and newer biomaterial scaffolds with these multiple factor-packed small molecules. Biomaterials for soft tissue wound healing are required to be able to adapt to the uneven morphology and mobility of the defect and also to have adhesiveness to the surrounding tissue to offer complete coverage as well as prevent exposure of the healing site to the environment. This adaptability ensures the most efficient biomimetics and can be offered by bio-responsive smart materials.
As demonstrated in Table 3, Wang et al. studied the effect of both free exosomes and those encapsulated in an FHE hydrogel on HUVEC cells and found that sustained release from the hydrogel supported a better growth by being less toxic to the cells and providing the required stimulus. The FHE (F127/OH-EPL) hydrogel offered a tissue-responsive behavior by having thermally responsive gelation, water retaining ability, as well as antibacterial and adhesive properties. Loading with exosomes has shown an enhanced angiogenetic potential in a diabetic mice model. They successfully demonstrated good injectability, self-healing, antibacterial activity, and stimuli-responsive exosome release. Similarly, a self-healing hydrogel consisting of a methyl-cellulose–chitosan hydrogel with placental mesenchymal stem cell (PMSC)-derived exosomes was also shown to be capable of diabetic wound healing, where neo tissue formation with similarity to natural skin was achieved.
Skin regeneration has long been associated with aesthetic and plastic surgery. Duncan et al. recently added exosomes with polydioxanone (PDO) threads in micro lifting surgery, which enhanced the bio stimulatory potential, and thus resulted in a faster clinical outcome. Neural regeneration is also an exciting area where exosomes have been tested and proven helpful. Exosomes from hGMSCs with chitin conduits were experimented on in a rat model by Rao et al., and the results showed improved repair of sciatic nerve damage.
4. Alternative Methods to Exosome Delivery
Aside from using exosome-embedded hydrogels to achieve a topical and sustained drug release effect, when exosomes are not encapsulated in hydrogels, they are delivered intravenously or topically. Sun and co-authors have designed a delivery method that can topically release exosome at the target sites. They also intravenously injected exosomes together with a SonoVueTM microbubble (Bracco Imaging) into mice, and then targeted the destruction of these microbubbles by ultrasound. They proved that the ultrasound-targeted microbubble destruction (UTMD) significantly increased the exosome infiltration and endocytosis. This method can be used as an alternate strategy for exosome delivery and endocytosis enhancement, but the disadvantage is that the exosomes would be quickly metabolized by the blood circulation system, causing a low utilization rate of the exosomes.
Multifunctional mesoporous bioactive glasses are also used for delivering therapeutic ions to the site of regeneration. Mesoporous silica nanoparticles (MSNs) as a drug-delivery system have recently been used for bone tissue engineering. These nanoparticles have a high specific surface area and pore volume, which allows for high loading of a drug and the controlled release of the drug from days to even weeks. Among other nanoparticles, using icariin loaded on micro/nano hybrid structured hydroxyapatite granules, has shown the potential for repairing femoral defects. In segmental bone repair, locally applied granulocyte colony-stimulating factor (G-CSF) has shown to enhance bone regeneration via neovascularization and osteogenesis. In a similar context, using a graphene-based miRNA transfection drug-delivery system, Dou and colleague discovered that the platelet-derived growth factor secreted by pre-osteoclasts (POC) can enhance bone mineral density, bone volume, and bone vascularization.
5. Conclusions
Tissue engineering with its requirements has created several new regenerative tools and biomaterials. Among the plethora of biomaterials, those combining hydrogels and stem cell therapy have shown promising results. Due to the numerous advantages of MSCs and their secretions (i.e., exosomes), several hydrogel formulations, such as PLGA, pDA, alginate, chitin PLGA/pDA, and FHE, have been reported to induce hard and soft tissue regeneration.
References 85
- 1.
- 2.
O’Brien F.J. Biomaterials & scaffolds for tissue engineering. Mater. Today. 2011;14:88-95.
Not in our library10.1016/s1369-7021(11)70058-x
- 3.
Trubiani O., Marconi G.D., Pierdomenico S.D., Piattelli A., Diomede F., Pizzicannella J. Human Oral Stem Cells, Biomaterials and Extracellular Vesicles: A Promising Tool in Bone Tissue Repair. Int. J. Mol. Sci. 2019;20:4987.
Not in our library10.3390/ijms20204987
- 4.
Akbari A., Jabbari N., Sharifi R., Ahmadi M., Vahhabi A., Seyedzadeh S.J., Nawaz M., Szafert S., Mahmoodi M., Jabbari E., et al. Free and hydrogel encapsulated exosome-based therapies in regenerative medicine. Life Sci. 2020;249:117447.
Not in our library10.1016/j.lfs.2020.117447
- 5.
Liu X., Yang Y., Li Y., Niu X., Zhao B., Wang Y., Bao C., Xie Z., Lin Q., Zhu L. Integration of stem cell-derived exosomes within situ hydrogel glue as a promising tissue patch for articular cartilage regeneration. Nanoscale. 2017;9:4430-4438.
Not in our library10.1039/c7nr00352h
- 6.
Pluchino S., Smith J.A. Explicating Exosomes: Reclassifying the Rising Stars of Intercellular Communication. Cell. 2019;177:225-227.
Not in our library10.1016/j.cell.2019.03.020
- 7.
Lai R.C., Yeo R.W.Y., Tan K.H., Lim S.K. Mesenchymal stem cell exosome ameliorates reperfusion injury through proteomic complementation. Regen. Med. 2013;8:197-209.
Not in our library10.2217/rme.13.4
- 8.
- 9.
Liu C., Su C. Design strategies and application progress of therapeutic exosomes. Theranostics. 2019;9:1015-1028.
Not in our library10.7150/thno.30853
- 10.
Lai R.C., Yeo R.W.Y., Tan S.S., Zhang B., Yin Y., Sze N.S.K., Choo A., Lim S.K. Mesenchymal Stem Cell Exosomes. Mesenchymal Stem Cell Therapy. 2013;39-61.
Not in our library
- 11.
- 12.
Sun Y., Shi H., Yin S., Ji C., Zhang X., Zhang B., Xu W. Human Mesenchymal Stem Cell Derived Exosomes Alleviate Type 2 Diabetes Mellitus by Reversing Pe-ripheral Insulin Resistance and Relieving Beta-Cell Destruction. ACS Nano. 2018;12:7613-7628.
Not in our library10.1021/acsnano.7b07643
- 13.
Shiue S.-J., Rau R.-H., Shiue H.-S., Hung Y.-W., Li Z.-X., Yang K.D., Cheng J.-K. Mesenchymal stem cell exosomes as a cell-free therapy for nerve injury–induced pain in rats. Pain. 2019;160:210-223.
Not in our library10.1097/j.pain.0000000000001395
- 14.
- 15.
Hazawa M., Tomiyama K., Saotome-Nakamura A., Obara C., Yasuda T., Gotoh T., Tanaka I., Yakumaru H., Ishihara H., Tajima K. Radiation increases the cellular uptake of exosomes through CD29/CD81 complex formation. Biochem. Biophys. Res. Commun. 2014;446:1165-1171.
Not in our library10.1016/j.bbrc.2014.03.067
- 16.
- 17.
- 18.
- 19.
Greco K.A., Franzen C.A., Foreman K.E., Flanigan R.C., Kuo P.C., Gupta G. PLK-1 Silencing in Bladder Cancer by siRNA Delivered with Exosomes. Urology. 2016;91:241.e1-241.e7.
Not in our library10.1016/j.urology.2016.01.028
- 20.
Nguyen D.C., Lewis H.C., Joyner C., Warren V., Xiao H., Kissick H.T., Wu R., Galipeau J., Lee F.E.-H. Extracellular vesicles from bone marrow-derived mesenchymal stromal cells support ex vivo survival of human antibody secreting cells. J. Extracell. Vesicles. 2018;7:1463778.
Not in our library10.1080/20013078.2018.1463778
- 21.
Wang X., Shah F.A., Vazirisani F., Johansson A., Palmquist A., Omar O., Ekström K., Thomsen P. Exosomes influence the behavior of human mesenchymal stem cells on titanium surfaces. Biomaterials. 2020;230:119571.
Not in our library10.1016/j.biomaterials.2019.119571
- 22.
Codispoti B., Marrelli M., Paduano F., Tatullo M. NANOmetric BIO-Banked MSC-Derived Exosome (NANOBIOME) as a Novel Approach to Regen-erative Medicine. J. Clin. Med. 2018;7:357.
Not in our library10.3390/jcm7100357
- 23.
Gonzalez-King H., García N.A., Ontoria-Oviedo I., Ciria M., Montero J.A., Sepúlveda P. Hypoxia Inducible Factor-1α Potentiates Jagged 1-Mediated Angiogenesis by Mesenchymal Stem Cell-Derived Exosomes. Stem Cells. 2017;35:1747-1759.
Not in our library10.1002/stem.2618
- 24.
- 25.
Li Z., Liu F., He X., Yang X., Shan F., Feng J. Exosomes derived from mesenchymal stem cells attenuate inflammation and demyelination of the central nervous system in EAE rats by regulating the polarization of microglia. Int. Immunopharmacol. 2019;67:268-280.
Not in our library10.1016/j.intimp.2018.12.001
- 26.
Zhang K., Zhao X., Chen X., Wei Y., Du W., Wang Y., Liu L., Zhao W., Han Z., Kong D., et al. Enhanced Therapeutic Effects of Mesenchymal Stem Cell-Derived Exosomes with an Injectable Hydrogel for Hindlimb Ischemia Treatment. ACS Appl. Mater. Interfaces. 2018;10:30081-30091.
Not in our library10.1021/acsami.8b08449
- 27.
Hansen-Algenstaedt N., Joscheck C., Wolfram L., Schaefer C., Müller I., Böttcher A., Deuretzbacher G., Wiesner L., Leunig M., Algenstaedt P., et al. Sequential changes in vessel formation and micro-vascular function during bone repair. Acta Orthop. 2006;77:429-439.
Not in our library10.1080/17453670610046361
- 28.
Huang C., Das A., Barker D., Tholpady S., Wang T., Cui Q., Ogle R., Botchwey E. Local delivery of FTY720 accelerates cranial allograft incorporation and bone formation. Cell Tissue Res. 2011;347:553-566.
Not in our library10.1007/s00441-011-1217-3
- 29.
Upadhyay A., Pillai S., Khayambashi P., Sabri H., Lee K.T., Tarar M., Zhou S., Harb I., Tran S.D. Biomimetic Aspects of Oral and Dentofacial Regeneration. Biomimetics. 2020;5:51.
Not in our library10.3390/biomimetics5040051
- 30.
Johnsen K.B., Gudbergsson J.M., Skov M.N., Pilgaard L., Moos T., Duroux M. A comprehensive overview of exosomes as drug delivery vehicles—Endogenous nanocarriers for tar-geted cancer therapy. Biochim. Biophys. Acta. 2014;1846:75-87.
Not in our library10.1016/j.bbcan.2014.04.005
- 31.
Kim M.K., Kim J. Properties of immature and mature dendritic cells: Phenotype, morphology, phagocytosis, and migration. RSC Adv. 2019;9:11230-11238.
Not in our library10.1039/c9ra00818g
- 32.
Kuate S., Doerr H.W., Überla K. Exosomal vaccines containing the S protein of the SARS coronavirus induce high levels of neutralizing antibodies. Virology. 2007;362:26-37.
Not in our library10.1016/j.virol.2006.12.011
- 33.
Torreggiani E., Perut F., Roncuzzi L., Zini N., Baglìo S.R., Baldini N. Exosomes: Novel effectors of human platelet lysate activity. Eur. Cells Mater. 2014;28:137-151.
Not in our library10.22203/ecm.v028a11
- 34.
Dos Santos F., Andrade P.Z., da Silva C.L., Cabral J.M.S. Scaling-up Ex Vivo Expansion of Mesenchymal Stem/Stromal Cells for Cellular Therapies. Mesenchymal Stem Cell Therapy. 2013;1-14.
Not in our library
- 35.
Jarmalavičiūtė A., Pivoriūnas A. Exosomes as a potential novel therapeutic tools against neurodegenerative diseases. Pharmacol. Res. 2016;113:816-822.
Not in our library10.1016/j.phrs.2016.02.002
- 36.
Santangelo L., Battistelli C., Montaldo C., Citarella F., Strippoli R., Cicchini C. Functional Roles and Therapeutic Applications of Exosomes in Hepatocellular Carcinoma. BioMed Res. Int. 2017;2017:2931813.
Not in our library10.1155/2017/2931813
- 37.
Hofmann L., Ludwig S., Vahl J.M., Brunner C., Hoffmann T.K., Theodoraki M. The Emerging Role of Exosomes in Diagnosis, Prognosis, and Therapy in Head and Neck Cancer. Int. J. Mol. Sci. 2020;21:4072.
Not in our library10.3390/ijms21114072
- 38.
- 39.
Luan X., Sansanaphongpricha K., Myers I., Chen H., Yuan H., Sun D. Engineering exosomes as refined biological nanoplatforms for drug delivery. Acta Pharmacol. Sin. 2017;38:754-763.
Not in our library10.1038/aps.2017.12
- 40.
Cited by papers we hold 4
- Clinical applications of stem cell-derived exosomes · 2024No notice
- Mesenchymal stromal/stem cell (MSC)-derived exosomes in clinical trials · 2023No notice
- Smart bioadhesives for wound healing and closure · 2023No notice
- Harnessing Tissue-derived Extracellular Vesicles for Osteoarthritis Theranostics · 2022No notice
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.